AP646A - Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. - Google Patents

Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. Download PDF

Info

Publication number
AP646A
AP646A APAP/P/1997/001092A AP9701092A AP646A AP 646 A AP646 A AP 646A AP 9701092 A AP9701092 A AP 9701092A AP 646 A AP646 A AP 646A
Authority
AP
ARIPO
Prior art keywords
fumagillol
preparation
fumagillin
drugs
ester
Prior art date
Application number
APAP/P/1997/001092A
Other languages
English (en)
Other versions
AP9701092A0 (en
Inventor
Jean-Michel Molina
Francis Deriyubm
Original Assignee
Sanofi Synthelabo
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Hopitaux Paris Assist Publique filed Critical Sanofi Synthelabo
Publication of AP9701092A0 publication Critical patent/AP9701092A0/xx
Application granted granted Critical
Publication of AP646A publication Critical patent/AP646A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1997/001092A 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. AP646A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number Publication Date
AP9701092A0 AP9701092A0 (en) 1997-10-31
AP646A true AP646A (en) 1998-04-27

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001092A AP646A (en) 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.

Country Status (25)

Country Link
US (1) US5900431A (cg-RX-API-DMAC10.html)
EP (1) EP0817626B1 (cg-RX-API-DMAC10.html)
JP (1) JP3260378B2 (cg-RX-API-DMAC10.html)
KR (1) KR100286920B1 (cg-RX-API-DMAC10.html)
CN (1) CN1072485C (cg-RX-API-DMAC10.html)
AP (1) AP646A (cg-RX-API-DMAC10.html)
AT (1) ATE172641T1 (cg-RX-API-DMAC10.html)
AU (1) AU706161B2 (cg-RX-API-DMAC10.html)
CA (1) CA2216623C (cg-RX-API-DMAC10.html)
CZ (1) CZ286821B6 (cg-RX-API-DMAC10.html)
DE (1) DE69600879T2 (cg-RX-API-DMAC10.html)
DK (1) DK0817626T3 (cg-RX-API-DMAC10.html)
EA (1) EA000150B1 (cg-RX-API-DMAC10.html)
ES (1) ES2128846T3 (cg-RX-API-DMAC10.html)
FR (1) FR06C0014I2 (cg-RX-API-DMAC10.html)
HU (1) HU224028B1 (cg-RX-API-DMAC10.html)
IS (1) IS2048B (cg-RX-API-DMAC10.html)
NO (1) NO315968B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ304906A (cg-RX-API-DMAC10.html)
OA (1) OA10515A (cg-RX-API-DMAC10.html)
PL (1) PL183378B1 (cg-RX-API-DMAC10.html)
SK (1) SK283883B6 (cg-RX-API-DMAC10.html)
TR (1) TR199701048T1 (cg-RX-API-DMAC10.html)
UA (1) UA41446C2 (cg-RX-API-DMAC10.html)
WO (1) WO1996030010A2 (cg-RX-API-DMAC10.html)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0817626T3 (da) * 1995-03-27 1999-07-12 Assist Publ Hopitaux De Paris Anvendelse af fumagillol og derivater deraf til fremstilling af lægemidler mod tarminfektioner
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
WO2000050084A1 (fr) * 1999-02-26 2000-08-31 Sanofi-Synthelabo Formulation stable contenant de la fumagilline
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
WO2009073445A2 (en) * 2007-11-28 2009-06-11 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
NZ590732A (en) * 2008-07-18 2012-09-28 Zafgen Inc Methods of treating an overweight or obese subject using fumagillin
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
EP2486004B1 (en) 2009-10-09 2017-05-03 Zafgen, Inc. Sulphone compounds for use in the treatment of obesity
WO2011085201A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Fumagillol type compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
BR112013001613A2 (pt) 2010-07-22 2016-05-24 Zafgen Inc compostos tricíclicos e métodos para fazer e usar os mesmos.
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
WO2012075020A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Treatment of obesity using non-daily administration of 6 - 0 - (4 - dimethylaminoethoxy) cinnamoyl fumagillol
WO2012103333A1 (en) 2011-01-26 2012-08-02 Zafgen Corporation Tetrazole compounds and methods of making and using same
MX342257B (es) 2011-03-08 2016-09-21 Zafgen Inc Derivados y análogos de oxaspiro [2.5] octano.
EA025526B1 (ru) 2011-05-06 2017-01-30 Зафджен Инк. Частично насыщенные трициклические соединения и способы их получения и применения
CN103748094B (zh) 2011-05-06 2016-06-29 扎夫根股份有限公司 三环磺酰胺化合物及其制备和使用方法
MX343688B (es) 2011-05-06 2016-11-16 Zafgen Inc Compuestos tricíclicos de sulfonamida y pirazolo y métodos para su fabricación y uso.
JP6035347B2 (ja) 2012-01-18 2016-11-30 ザフゲン,インコーポレイテッド 三環式スルホンアミド化合物ならびにその作製および使用方法
JP2015509102A (ja) 2012-01-18 2015-03-26 ザフゲン,インコーポレイテッド 三環式スルホン化合物並びにその作製および使用方法
AU2013259760A1 (en) 2012-05-07 2014-11-20 Zafgen, Inc. Polymorphic salt of the oxalate salt of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol and methods of making and using same
CA2872876A1 (en) 2012-05-08 2013-11-14 Zafgen, Inc. Treating hypothalamic obesity with metap2 inhibitors
WO2013169860A1 (en) 2012-05-09 2013-11-14 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
JP6169716B2 (ja) 2012-11-05 2017-07-26 ザフゲン,インコーポレイテッド 肝疾患を治療する方法
AU2013337288A1 (en) 2012-11-05 2015-05-21 Zafgen, Inc. Tricyclic compounds for use in the treatment and/or control of obesity
CN104870433A (zh) 2012-11-05 2015-08-26 扎夫根股份有限公司 三环化合物及其制备方法和用途
JP2016513722A (ja) 2013-03-14 2016-05-16 ザフゲン,インコーポレイテッド 腎臓病及び他の疾患の治療方法
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
CA2082804A1 (en) * 1990-07-27 1992-01-28 Theodore Maione Methods and compositions for treatment of angiogenic diseases
DK0817626T3 (da) * 1995-03-27 1999-07-12 Assist Publ Hopitaux De Paris Anvendelse af fumagillol og derivater deraf til fremstilling af lægemidler mod tarminfektioner
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
WO1998005293A2 (en) * 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin

Also Published As

Publication number Publication date
ES2128846T3 (es) 1999-05-16
IS4557A (is) 1997-09-11
JP3260378B2 (ja) 2002-02-25
AP9701092A0 (en) 1997-10-31
CN1179715A (zh) 1998-04-22
PL183378B1 (pl) 2002-06-28
AU706161B2 (en) 1999-06-10
HUP9801220A2 (hu) 1999-09-28
UA41446C2 (uk) 2001-09-17
US5900431A (en) 1999-05-04
SK130797A3 (en) 1998-03-04
FR06C0014I2 (cg-RX-API-DMAC10.html) 2006-12-29
OA10515A (fr) 2002-04-24
HU224028B1 (hu) 2005-05-30
EP0817626A2 (fr) 1998-01-14
JPH11506421A (ja) 1999-06-08
EA000150B1 (ru) 1998-10-29
WO1996030010A3 (fr) 1996-11-28
CA2216623C (en) 2005-05-31
NO315968B1 (no) 2003-11-24
MX9707150A (es) 1998-07-31
CN1072485C (zh) 2001-10-10
FR06C0014I1 (cg-RX-API-DMAC10.html) 2006-11-17
NZ304906A (en) 1999-06-29
WO1996030010A2 (fr) 1996-10-03
SK283883B6 (sk) 2004-04-06
EP0817626B1 (fr) 1998-10-28
CZ304997A3 (en) 1997-12-17
NO974466D0 (no) 1997-09-26
DE69600879D1 (de) 1998-12-03
KR19980703271A (ko) 1998-10-15
DE69600879T2 (de) 1999-06-02
EA199700267A1 (ru) 1998-04-30
KR100286920B1 (ko) 2001-04-16
ATE172641T1 (de) 1998-11-15
HUP9801220A3 (en) 2001-10-29
CA2216623A1 (en) 1996-10-03
AU5278696A (en) 1996-10-16
TR199701048T1 (xx) 1998-01-21
PL322470A1 (en) 1998-02-02
CZ286821B6 (en) 2000-07-12
NO974466L (no) 1997-09-26
DK0817626T3 (da) 1999-07-12
IS2048B (is) 2005-09-15

Similar Documents

Publication Publication Date Title
AP646A (en) Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.
US5348744A (en) Antidiarrheal compositions containing loperamide hydrochloride and a saccharide
US4101647A (en) Oral dosage form for X-ray contrast media containing a pharmaceutically acceptable base and method of use thereof
AU608853B2 (en) Inhibitors of glycoprotein processing having anti- retroviral activity
JPH0232093A (ja) 抗レトロウィルスジフルオロ化ヌクレオシド類
EP0190851B1 (en) Improved antiinflammatory composition
JPH0610141B2 (ja) エイズウイルス性疾患処置剤
MXPA97007150A (en) Use of fumagilol and its derivatives to prepare medicines intended to combat intestine infections
AU748883B2 (en) Method of treating pulmonary hypertension
US6593329B1 (en) Method for the treatment or prevention of coronary graft vasospasm
US20230144875A1 (en) Highly purified eicosapentaenoic acid, as free fatty acid for treatment of coronaviruses and specifically novel coronavirus-19 (covid-19)
WO1992007564A2 (en) Method of treating demyelinating disease
US7485642B2 (en) Method for treating septic shock
EP0402477B1 (en) Use of isocarbacyclins for preventing or treating organ diseases
JPH0132804B2 (cg-RX-API-DMAC10.html)
JPH04266822A (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
US20070093519A1 (en) Anti-emetic uses of cannabinoid analogs
US20040044016A1 (en) Antiviral agents
JPS58210010A (ja) 抗腫瘍剤
JPH02174721A (ja) 脂質低下剤
JPH0899883A (ja) 膵炎治療剤